Versant backs a rebooted Tarveda with $30M round for pipeline development
Just a year after raising $38 million to reboot his company, Tarveda Therapeutics CEO Drew Fromkin has hauled in a $30 million round to fund …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
